Payment overview · 2025
General Payments
$1,111.16
32 reported records · 9 companies
Healthcare provider profile · identity verified
Boris Itskovich, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1235197252
Verified facts
What the public records show
CMS Open Payments records show Boris Itskovich, M.D received $1,111.16 in general payments during 2025 across 32 reported records.
ABBVIE INC. accounted for 27.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Linzess, Ozempic, Rybelsus, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Nexium by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $300.88 | 27.1% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $247.20 | 22.2% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $206.06 | 18.5% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $178.45 | 16.1% | 3 | 2025 |
| Cumberland Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $70.86 | 6.4% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $36.49 | 3.3% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.94 | 2.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.44 | 2.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.84 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,111.16 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $220.84 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $206.06 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $194.29 | 8 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $125.30 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $80.04 | 4 | 2025 |
Source payment records
|
|||||
| KRISTALOSE Normalized: kristalose |
Drug | Cumberland Pharmaceuticals, Inc. | $70.86 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $66.65 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $53.15 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $52.91 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $45.44 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $36.49 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.59 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $27.94 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 177 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 169 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 145 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 77 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
169 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
100 | 15 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
77 | 18 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
25 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
177 | 30 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
145 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 709 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 681 | 119 |
| Metformin Hcl | Metformin Hcl | 444 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 414 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 356 | 60 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 356 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 316 | 41 |
| Furosemide | Furosemide | 260 | 50 |
| Omeprazole | Omeprazole | 239 | 65 |
| Eliquis | Apixaban | 235 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 230 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 209 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 209 | 49 |
| Potassium Chloride | Potassium Chloride | 202 | 33 |
| Januvia | Sitagliptin Phosphate | 196 | 26 |
| Dexlansoprazole Dr | Dexlansoprazole | 178 | 25 |
| Simvastatin | Simvastatin | 178 | 27 |
| Farxiga | Dapagliflozin Propanediol | 177 | 30 |
| Linzess | Linaclotide | 169 | 23 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 168 | 31 |
| Allopurinol | Allopurinol | 148 | 22 |
| Ozempic | Semaglutide | 145 | 26 |
| Losartan Potassium | Losartan Potassium | 141 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 141 | 23 |
| Alendronate Sodium | Alendronate Sodium | 140 | 28 |
| Glipizide Er | Glipizide | 133 | 21 |
| Labetalol Hcl | Labetalol Hcl | 130 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 125 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 122 | 18 |
| Tradjenta | Linagliptin | 119 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 114 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 106 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 104 | 18 |
| Synthroid | Levothyroxine Sodium | 100 | 15 |
| Buspirone Hcl | Buspirone Hcl | 99 | 18 |
| Carvedilol | Carvedilol | 95 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 88 | 13 |
| Vascepa | Icosapent Ethyl | 84 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 81 | 30 |
| Gabapentin | Gabapentin | 81 | 24 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 81 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 78 | 63 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 18 |
| Zenpep | Lipase/Protease/Amylase | 77 | 18 |
| Trazodone Hcl | Trazodone Hcl | 72 | 15 |
| Mounjaro | Tirzepatide | 70 | 14 |
| Glipizide | Glipizide | 68 | suppressed |
| Memantine Hcl | Memantine Hcl | 66 | 13 |
| Meclizine Hcl | Meclizine Hcl | 63 | 24 |
| Enalapril Maleate | Enalapril Maleate | 60 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 54 | 18 |
| Celecoxib | Celecoxib | 54 | 20 |
| Donepezil Hcl | Donepezil Hcl | 54 | 12 |
| Jardiance | Empagliflozin | 53 | suppressed |
| Lisinopril | Lisinopril | 53 | 12 |
| Single Use Swab | Alcohol Antiseptic Pads | 52 | 18 |
| Myrbetriq | Mirabegron | 51 | 11 |
| Atenolol | Atenolol | 49 | suppressed |
| Ibuprofen | Ibuprofen | 49 | 35 |
| Irbesartan | Irbesartan | 49 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 46 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 33 |
| Bystolic | Nebivolol Hcl | 41 | suppressed |
| Creon | Lipase/Protease/Amylase | 41 | suppressed |
| Ezetimibe | Ezetimibe | 40 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 34 |
| Finasteride | Finasteride | 38 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 38 | 13 |
| Ketoconazole | Ketoconazole | 35 | 22 |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Ranolazine Er | Ranolazine | 34 | suppressed |
| Colchicine | Colchicine | 33 | 14 |
| Dexilant | Dexlansoprazole | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Rybelsus | Semaglutide | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Metolazone | Metolazone | 28 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 15 |
| Prolia | Denosumab | 25 | 14 |
| Invokana | Canagliflozin | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Naproxen | Naproxen | 24 | 14 |
| Nexium | Esomeprazole Magnesium | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 21 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Benicar | Olmesartan Medoxomil | 20 | suppressed |
| Brilinta | Ticagrelor | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 19 |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 19 | 12 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 18 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | 15 |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 11 |
| Glipizide Xl | Glipizide | 16 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 16 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Veozah | Fezolinetant | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Azithromycin | Azithromycin | 14 | 13 |
| Betamethasone Valerate | Betamethasone Valerate | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | 11 |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Tribenzor | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,111.16 · 32 records | ABBVIE INC. | BREZTRI, CREON, EVENITY, FARXIGA, IBSRELA, JARDIANCE, KRISTALOSE, LINZESS, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, XIFAXAN, ZENPEP | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error